Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Esperion Therapeutics
Esperion Therapeutics
(ESPR)
Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Nexletol
Bempedoic acid
2020-02-21
2025-2040
Hypercholesterolemia
,
Dyslipidemias
,
Atherosclerosis
,
Hyperlipoproteinemia type ii
,
Familial combined hyperlipidemia
Nexlizet
Bempedoic acid
,
Ezetimibe
2020-02-26
2025-2040
Hypercholesterolemia
,
Dyslipidemias
,
Atherosclerosis
,
Hyperlipoproteinemia type ii
,
Familial combined hyperlipidemia
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Bempedoic acid
type 2 diabetes mellitus
,
diabetes mellitus
,
hypertension
,
hypertriglyceridemia
,
hyperlipoproteinemia type ii
,
hiv infections
,
inflammation
,
hyperlipoproteinemias
,
hypercholesterolemia
,
dyslipidemias
,
hyperlipidemias
,
cardiovascular diseases
,
atherosclerosis
,
drug-related side effects and adverse reactions
,
st elevation myocardial infarction
,
non-st elevated myocardial infarction
,
myocardial infarction
,
coronary artery disease
,
acute coronary syndrome
,
atherosclerotic plaque
,
metabolic diseases
,
lipid metabolism disorders
,
familial combined hyperlipidemia
,
pregnancy
,
infarction
,
liver diseases
,
non-alcoholic fatty liver disease
,
fatty liver
Ezetimibe
pharmacokinetics
,
drug interactions
,
immunosuppression therapy
,
neoplasms
,
pharmacological phenomena
,
endometriosis
,
therapeutic equivalency
,
endometrial neoplasms
,
acute kidney injury
,
alopecia areata
,
alopecia
,
pancreatic ductal carcinoma
,
pancreatic neoplasms
,
adenocarcinoma
,
healthy volunteers/patients
,
chronic hepatitis
,
chronic hepatitis d
,
hepatitis d
,
prostatic neoplasms
,
diabetic neuropathies
,
polyneuropathies
,
oxidative stress
,
lipidoses
,
hyperlipoproteinemia type ii
,
homozygous familial hypercholesterolemia
,
inborn errors lipid metabolism
,
inborn errors metabolism
,
essential hypertension
,
vascular diseases
,
aortic valve stenosis
,
pathologic constriction
,
left ventricular hypertrophy
,
hypertrophy
,
diabetic nephropathies
,
infections
,
kidney transplantation
,
lung transplantation
,
communicable diseases
,
insulin resistance
,
weight gain
,
hypercholesterolemia
,
dyslipidemias
,
coronary artery disease
,
hyperlipidemias
,
coronary disease
,
atherosclerosis
,
myocardial ischemia
,
heart diseases
,
cardiovascular diseases
,
diabetes mellitus
,
type 2 diabetes mellitus
,
hyperlipoproteinemias
,
acute coronary syndrome
,
syndrome
,
myocardial infarction
,
infarction
,
metabolic syndrome
,
hypertension
,
atherosclerotic plaque
,
hepatitis
,
hepatitis a
,
hypertriglyceridemia
,
inflammation
,
kidney diseases
,
familial combined hyperlipidemia
,
stroke
,
peripheral arterial disease
,
chronic renal insufficiency
,
st elevation myocardial infarction
,
metabolic diseases
,
hepatitis c
,
non-alcoholic fatty liver disease
,
fatty liver
,
ischemic stroke
,
hiv infections
,
lipid metabolism disorders
,
drug-related side effects and adverse reactions
,
peripheral vascular diseases
,
chronic hepatitis c
,
ischemia
,
liver diseases
,
type 1 diabetes mellitus
,
non-st elevated myocardial infarction
,
cognitive dysfunction
,
hiv
,
alcoholic fatty liver
,
carotid artery diseases
,
preconception care
,
vitamin d deficiency
,
endocrine system diseases
,
nutritional and metabolic diseases
,
left ventricular dysfunction
,
vascular stiffness
,
transplantation
,
renal insufficiency
,
atrial fibrillation
,
magnetic resonance imaging
,
neuropsychology
,
hemostasis
,
arteriosclerosis
,
chronic disease
,
vascular calcification
,
calcinosis
,
intracranial arteriosclerosis
,
inferior wall myocardial infarction
,
stable angina
,
cerebrovascular disorders
,
prediabetic state
,
hyperlipoproteinemia type v
,
lactation
,
genetic testing
,
hyperlipoproteinemia type iii
,
arthrogryposis
,
medication adherence
,
treatment adherence and compliance
,
patient compliance
,
motivational interviewing
,
compliance
,
intestinal diseases
,
heart disease risk factors
,
glucose intolerance
,
cholecystitis
,
acalculous cholecystitis
,
alzheimer disease
,
obesity
,
covid-19
,
coronavirus infections
,
pregnancy
,
breast feeding
,
disease progression
,
thrombocytopenic purpura idiopathic
,
thrombocytopenia
,
cerebral infarction
,
secondary prevention
,
cerebral small vessel diseases
,
percutaneous coronary intervention
,
cardiomyopathies
Serine
healthy volunteers/patients
,
pharmacokinetics
,
crush injuries
,
neoplasms
,
thrombocytopenia
,
patent foramen ovale
,
paradoxical embolism
,
female genital neoplasms
,
renal cell carcinoma
,
carcinoma
,
kidney diseases
,
heart diseases
,
embolic stroke
,
cerebral infarction
,
ischemic stroke
,
coronary artery bypass
,
leukemia
,
lymphoma
,
precursor cell lymphoblastic leukemia-lymphoma
,
lymphoid leukemia
,
transient ischemic attack
,
sickle cell anemia
,
hematoma
,
atrial flutter
,
covid-19
,
coronavirus infections
,
coronavirus
,
atrial fibrillation
,
thrombosis
,
thromboembolism
,
embolism
,
venous thromboembolism
,
venous thrombosis
,
pulmonary embolism
,
chronic kidney failure
,
stroke
,
syndrome
,
acute coronary syndrome
,
multiple myeloma
,
plasma cell neoplasms
,
right ventricular dysfunction
,
pulmonary infarction
,
infarction
,
ventricular dysfunction
,
pulmonary heart disease
,
antiphospholipid syndrome
,
renal insufficiency
,
hemorrhage
Mevalotin
drug interactions
,
hyperlipidemias
,
hyperlipoproteinemia type iii
,
hyperlipoproteinemias
,
hypercholesterolemia
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use